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ABSTRACT
األهداف: األدوية املضادة للتخثر الفموي )OACs( قد يكون 
لها آثار جانبية كبيرة مبا في ذلك النزيف. هناك حاجة إلى طريقة 
كان   .OACs استخدام  نحو  املرضى  مواقف  لتقييم  بها  موثوق 
الغرض من هذه الدراسة هو تطوير مقياس موثوق به ميكنه قياس 
.OACs مواقف األفراد الذين يستخدمون
األفراد  من   296 مع  املنهجية  الدراسة  هذه  أجريت  الطريقة: 
وزيارة  األقل  على  أشهر  ستة  ملدة   OACs باستخدام  املتابعني 
عيادات أمراض القلب واألعصاب في مستشفى في تركيا خالل 
عام 2017. مت استخدام مجموعة من 20 بنًدا لبناء املقياس وكانت 
جميع العناصر وجدت مناسبة بعد حتليل صحة احملتوى واالختبار 
األولي. مت فحص صالحية املصادقة باستخدام حتليل عامل التأكيد 
.)EFA( وحتليل عامل االستكشاف )CFA(
النتائج: أظهرت قيمة كايزر-ماير-أولكني )KMO( للمقياس 
مناسًبا  كان  العينة  حجم  أن  بارتليت  اختبار  ونتائج   )0.79(
لتحليل العوامل )p<0.001(. بلغ مجموع معامل ألفا كرونباخ 
احملتوى  صالحية  لتقييم  العوامل  حتليل  حدد   .0.83 للمقياس 
من املقياس أربعة عوامل )التباين، %54(. مت حساب استخدام 
اجلذر  متوسط   ،   CFA ، Chi-square/df في  مسار  مخطط 
 ،  )CFI( املقارن  التوافق  مؤشر   ،)SRMR( املتبقي  املوحد 
 2.807 ليكون   )RMSEA( التقريب في  اجلذر  متوسط  وخطأ 
، 0.093، 0.879 ، و 0.078 ، على التوالي.
 )OACAS( اخلامتة: لقد وجدنا أن مقياس سلوك التخثر الفموي
الذي قمنا بتطويره كان له مصداقية عالية وصحة.
Objectives: To develop a reliable scale that can measure 
the attitudes of individuals using oral anticoagulant 
drugs (OACs).
Methods: This methodological study was conducted 
with 296 followed-up individuals using OACs for 
at least 6 months and visiting the cardiology and 
neurology clinics of a hospital in Turkey during 2017. 
A 20-item pool was used to construct the scale and 
all items were found suitable after content validity 
analysis and preliminary testing. Construct validity 
was examined using confirmatory factor analysis 
(CFA) and exploratory factor analysis (EFA).
Results: The Kaiser-Meyer-Olkin (KMO) value of the 
scale (0.79) and results of Bartlett’s test showed that the 
sample size was suitable for factor analysis (p<0.001). 
The total Cronbach alpha coefficient of the scale 
was 0.83. Factor analysis to assess construct-content 
validity of the scale identified 4 factors (variance, 
54%). Using a path diagram in CFA, Chi-square/df 
ratio values was calculated at 2.807, standardized root 
mean square residual (SRMR) at 0.093, comparative 
fit index (CFI) at 0.879, and root mean square error 
of approximation (RMSEA) at 0.078. 
Conclusions: We found that the OACAs we developed 
had high reliability and validity.
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Various drugs are used for the diagnosis and treatment of diseases in clinics and nurses have important 
responsibilities both in the administration of drugs and 
patient training. Educating individuals regarding safe 
drug use, especially with respect to increased drug use 
after discharge, has assumed increasing importance due 
to the increasing number of chronic diseases in recent 
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years.1,2 Oral anticoagulant (OAC) drugs constitute 
a group of drugs that inhibit thrombus formation or 
thrombus growth in arteries and veins by disrupting 
the activity and synthesis of coagulation factors. Oral 
anticoagulant drugs taken orally attain the maximum 
blood level within 2-8 hours, with a half-life of 
40-48 hours and physiological effects lasting for 5 days.1-4 
Side effects of OAC drugs such as bleeding and clot 
formation occur frequently during long-term treatment 
of neurological and cardiovascular diseases. Narrow and 
variable therapeutic ranges, interactions with food and 
drug groups, and individual characteristics can lead to 
life-threatening problems during drug use. 4-6 
Jeffree et al7 reported that the most important side 
effect of OAC use is bleeding and vital problems can be 
experienced according to the severity of the bleeding. 
In the 1993-2006 study of the Adverse Evert Reporting 
System (AERS),8 it was reported that there were 9766 
people in America who were registered to the emergency 
service due to bleeding, 8415 of them were using 
anticoagulants and 999 of died.7 Similarly, Serebruany 
et al8 reported that 128,267 drug deaths in the AERS 
were associated with 14,917 OACs reports.8 Piazza 
et al9 noted that 48% of adverse drug errors reported 
in a hospital between 2004 and 2009 were associated 
with anticoagulant. It was found to be limited studies 
on the subject in Turkey. Doğu & Acaroğlu1 reported 
that 52.4% of individuals using OAC had experience 
of bleeding. As seen in the results of this study are 
significant side effects that cannot be ignored; bleeding 
risk in patients using oral anticoagulants.1 
Mortality, due to the use of anticoagulants, decreases 
prevention of drug interactions and compliance with 
treatment.1,10 Health behaviors are the set of behaviors 
that an individual believes such as practices for the 
protection of health, the development of health, 
and  the safe use of medicine.  Oral anticoagulant in 
drug use behavior change is possible by informing 
the individual.  There is a need to analyze factors 
that increase individuals’ understanding of the above 
issues and ensure lasting behavior change.1,3,11,12 In 
the present study, the side effects of OAC medication 
are significantly higher. Therefore, determining the 
attitudes of individuals in using OACs is required for 
clarity and to identify deficiencies.  Starting from this 
idea to determine the attitudes of individuals for using 
OAC is required so that we can emerge as clear and 
reveal the deficiencies. Keeping individuals informed 
about OAC drug use, developing appropriate and 
accessible solutions for patients to make necessary 
lifestyle changes, and safe drug use play an important 
role in the achievement of the expected therapeutic 
effect. The purpose of the present study was to develop 
a scale aimed at determining the attitudes of individuals 
towards OAC use and to support the educational 
content in this context.
Methods. This was a methodological study 
conducted to develop an oral anticoagulant-use attitude 
scale (OACAS) cross section and descriptive aimed at 
determining the attitudes of individuals towards oral 
anticoagulant treatment.
During the development of the scale, items were 
selected to reflect the goal of the scale accurately and the 
main points considered were consistency with literature, 
clarity, and comprehensibility of terms. A total of 20 
scale items were presented to members of the faculty 
of neurology (n=3), cardiology (n=2), pharmacology 
(3), biochemistry (n=1), nursing (n=8), pharmaceutics 
(n=2), Turkish language (n=2), and of statistics (n=1); 
their expert opinions were sought to determine whether 
the items were appropriate for the aim of the assessment, 
whether they represented the area of the assessment, and 
whether they include terms different than the intended 
ones. Content validity analyses were performed after the 
expert opinions were obtained. All the 20 items selected 
to determine attitudes towards OAC use were found to 
result in sufficient validity for the scale, with a Content 
Validity Index (CVI) value greater than 0.42 among 20 
experts. The total content validity ratio of the scale was 
calculated as 0.79.
The study was permitted by the management of 
the institutions where the study was conducted and 
approval was obtained from the Ethics Committee of 
Sakarya University, Sakarya, Turkey. Individuals who 
constituted the research sample were informed about the 
purpose and duration of the study, and the expectations 
from them. Informed consent to participate in the study 
was obtained.
The study group consisted of individuals (n=296) 
who applied to the cardiology and neurology outpatient 
clinics of a single research and education hospital in 
the province of Sakarya, Turkey, between March and 
December 2017. 
Inclusion criteria to the study were patients who 
used OAC drugs for 6 months and above, having at 
least 18 years of age, well competent in using Turkish 
language, and volunteering to participate. The exclusion 
Disclosure. Authors have no conflict of interests, and the 
work was not supported or funded by any drug company.
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criteria were patients who used OAC drugs for less 
than 6 months, having bad health condition, and have 
communication problem. 
The data were collected 5 days a week at the outpatient 
clinic through a face to face interview with all volunteers 
during Tuesday and Thursday. In the literature, it is 
stated that the number of samples should be at least 
10 times the scale item in scale development.13 This 
was taken into consideration in the number of samples. 
Test-retest analysis of the scale was performed with 20 
individuals. The scale was evaluated with 20 individuals 
to assess comprehensibility by performing a preliminary 
study and unexplained expressions were edited.
Data were collected using a patient information form 
and the OACAS. The patient’s information form was 
consisting 10 questions addressing sociodemographic 
information of the patients including age, gender, and 
education. Oral anticoagulant-use attitude scale is a 
5-point Likert-type scale consisting of 20 items to tell 
how well a patient with OAC manages attitude. The 
item contents regarding how to manage attitude were 
designed specifically on OAC-use. The increase in the 
scale score showed that the attitude was positive and 
high. Participants were asked to read each statement in 
the scale and to respond based on whether or not they 
agreed with each item, by marking one of the options 
listed as following; 1) strongly disagree, 2) disagree, 3) 
undecided, 4) agree, 5) strongly agree. The maximum 
score in the scale was 100 and the minimum score was 
20. it took approximately 10-15 minutes to fill. 
Statistical analysis. Expert opinions were obtained 
and factor analysis was performed to assess the validity of 
the scale development; test-retest analysis and Cronbach 
alpha analysis were performed to assess reliability. Prior 
to factor analysis, the Kaiser-Meyer-Olkin (KMO) test 
and the Bartlett sphericity test, which evaluate correlation 
among the items were used to assess suitability of the data 
to the sample group and sample sufficiency. Construct 
validity was examined using exploratory factor analysis 
(EFA) and confirmatory factor analysis (CFA). The 
main factor constructs of the scale were evaluated 
using EFA; information regarding quality of the factors 
determined, general construction of the scale, and the 
extent to which the scale represented attitude towards 
OAC use were evaluated via CFA. Confirmatory factor 
analysis  was performed using AMOS (IBM SPSS 
AMOS, Version 23.0. Armonk, NY: IBM Corp.)
Descriptive analyses were performed to provide 
information on general characteristics of the study 
population. The Kolmogorov-Smirnov test was used to 
evaluate whether the distribution of scales was normal 
and all scales were found to display a normal distribution. 
Pearson’s correlation coefficients were calculated to 
assess correlation between test-retest total scores of 
the scales, separately for subscales. The scales were 
represented as mean ± standard deviation. A p<0.05 was 
considered significant. Analyses were performed using 
commercially available software (IBM SPSS Statistics, 
Version 23.0. Armonk, NY: IBM Corp.)
Results. Findings related to the study of scale 
development were examined under the headings of 
sociodemographic characteristics, KMO for validity 
and exploratory and confirmatory factor analysis, 
test-retest for reliability, correlation-based item analysis, 
and internal consistency analysis.
It was found that of the individuals, 53% were over 
65 years old, 54.4% were male, 82.8% were married, 
31.8% were secondary school graduates, 76% were not 
employed, and 50.7 % had income equal to expenses. It 
was further determined that 58.4% had a heart disease, 
41.6% used OAC due to a neurological disorder, and 
nearly half (46.6%) had another chronic disease.
Construct validity. The scale was tested using EFA 
and CFA. In the first stage of the factor analysis, the 
suitability of the data obtained from preliminary 
application of the scale for factor analysis was tested 
using KMO and Bartlett’s tests. The KMO coefficient 
was found to be 0.795, and the Chi-square value 
obtained from Bartlett’s test was found to be significant 
at the advanced level (χ2=2566.27; p<0.001). The 
sample size was found to be suitable and sufficient for 
factor analysis.
Exploratory factor analysis. This was performed for 
the data set to evaluate construct validity of the scale 
and to determine and assess factor loads of the items in 
the scale. Based on the analysis, the scale was reduced 
to 4 subscales because 4 factors were found to have an 
eigenvalue greater than one (Figure 1). The total variance-
explaining ratio for the 7-item first sub-dimension 
(attitude towards safe environment and food interaction 
[SE]) was calculated to be 25.5%, with 12.93% for 
the 3-item; 2nd sub-dimension (attitude toward 
safe medication [SM]), 9.1% for the 5-item; 3rd 
sub-dimension (prevention of trauma and attitudes 
appropriate approach [PT]), and 6.9% for the 5-item; 
4th sub-dimension (attitudes toward the prevention of 
potential [PR]); the total variance-explaining ratio of 
all the 4 sub-dimensions was calculated to be 54.37% 
(Table 1).
Confirmatory factor analysis. In the final stage, the 
fit indices were examined using the CFA model, which 
was formed as a 4-sub-dimension model. The 4-factor 
construct of the scale consisting of 20 terms showed 
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good suitability. In order to verify the construct validity 
of the scale, a path diagram (Figure 2) was drawn based 
on CFA and the fit indices were calculated. Based on 
this, Chi-square (χ2)/degrees of freedom (df ) were 
calculated to be 2.807, standardized root mean square 
residual (SRMR) to be 0.093, adjusted goodness of fit 
index (AGFI) to be 0.854, comparative fit index (CFI) to 
be 0.879, and root mean square error of approximation 
(RMSEA) to be 0.078 (Table 2).
Scale reliability. Scale reliability was evaluated using 
internal consistency (Cronbach alpha) and test-retest 
methods.
Internal consistency (Cronbach alpha) reliability. 
Cronbach alpha reliability coefficients were calculated 
to assess whether the items involved in each factor in 
the scale measured the relevant factor and therefore 
whether all the items included in the scale measured the 
desired characteristic. The Cronbach alpha coefficients 
were calculated to be 0.841 for the first sub-dimension 
(SE), 0.937 for the 2nd sub-dimension (SM), 0.617 for 
the 3rd sub-dimension (PR), and 0.641 for 4th sub-
dimension (PT). The Cronbach alpha coefficient for the 
entire scale was calculated to be 0.838, and the scale was 
therefore considered reliable (Table 1).
Test-retest reliability. To determine reliability of 
the scale over time, test-retest analysis was performed 
by asking 20 individuals to fill in the scale again after 
15 days. To assess the relationship between the scores 
obtained from the scale items and the total score, 
correlation-based item analysis was performed for 
all the items. When scale reliability was evaluated 
using test-retest analysis, a statistically significant 
consistency between the 2 measurements (p>0.05) 
Table 1 - The results of factor analysis, item factor loads and internal consistency analysis of the OACAS.








Attitude towards safe 
environment and food 
Interaction 
OACAS01 0.856 0.768 0.790 0.841
OACAS02 0.839 0.739 0.796
OACAS03 0.716 0.625 0.815
OACAS04 0.687 0.577 0.824
OACAS05 0.640 0.551 0.826
OACAS06 0.600 0.541 0.828
OACAS07 0.475 0.360 0.849
Attitude toward safe 
sedication
OACAS08 0.907 0.856 0.919 0.937
OACAS09 0.906 0.889 0.892
OACAS10 0.863 0.864 0.912
Prevention of 
trauma and attitudes 
appropriate approach
OACAS11 0.853 0.424 0.539 0.617
OACAS12 0.850 0.403 0.545
OACAS13 0.458 0.379 0.558
OACAS14 0.425 0.367 0.564
OACAS15 0.414 0.295 0.606
Attitudes toward the 
prevention of potential 
risks
OACAS16 0.667 0.536 0.533 0.641
OACAS17 0.657 0.548 0.515
OACAS18 0.588 0.348 0.621
OACAS19 0.559 0.282 0.636
OACAS20 0.540 0.322 0.630
Total variance-explaining ratio              54.369 %
OACAS - oral anticoagulant-use attitude scale
Figure 1 - Screen plot and eigenvalue of exploratory factor analysis.
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was found. The correlation (r) between the first and 
second measurement scores of the scale was found to 
be statistically significant (Table 3). The total average 
OAC scale score was calculated to be 47.39±12.78. 
The total sub-dimension scores of the scale were 
20.08±7.22 for SE, 7.64±4.46 for SM, 9.95±3.34 for 
PT, and 9.70±3.38 for PR (Table 4).
The results of the correlation analysis to identify the 
relationship between the total score and sub-dimension 
scores of the scale are shown in Table 5. In general, it 
was found that all sub-dimensions had a statistically 
significant relationship with each other and with 
the total scale dimension, with the exception of the 
relationship between the SE sub-dimension and the PR 
sub-dimension which was not significant.
Discussion. In the present study, a 20-item 
OACAS consisting of 4 sub-dimensions comprising 
SE, SM, PT, and PR was developed to determine the 
attitudes of individuals towards OAC use. The scale was 
found to be valid and reliable, and to have sufficient 
psychometric properties.
The safe use of oral anticoagulant drugs and the 
satisfaction of the individual in this regard affect attitude 
towards drug use. Due to the frequent side effects and 
the narrow therapeutic range of OACs, patient attitude 
is one of the issues that need to be emphasized in Turkey 
as well as in other parts of the world. Individuals who 
receive OACs are expected to gain a positive attitude and 
become familiar with the drug use. Through the scale 
we developed, appropriate management of drug use and 
areas requiring training or information can be assessed 
easily. No significant difference was expected between 
measurements performed days apart, and this was found 
to be the case. Analyses performed to assess reliability 
of the scale revealed no change in the parameters with 
Table 2 - Fit indices, calculated by confirmatory factor analysis.
Fit Indices Referans values1,13 Value
χ2 /df <0 x2/df <39 2.807
Standardized root mean square residual (SRMR) SRMR <0.12,4,7,15 0.093
Goodness-of-fit index (GFI) <0.90 GFI <0.95 0.854
Adjusted goodness of fit index (AGFI)  <0.85 AGFI <0.903,6, 7 0.813
Root mean square residual (RMR) RMR <12,6 0.156
Incremental fit index (IFI) IFI ≥0.905 0.880
Normed fit index (NFI) <0.90 NFI <0.954,14 0.825
Parsimonious goodness of fit index (PGFI) PGFI ≥0.506 0.667
Parsimony normed fit index (PNFI) PNFI ≥0.506 0.712
Root mean square error of approximation (RMSEA) <0.05 RMSEA <0.082,4,7,15 0.078
Comparative fit index (CFI) <0.95 CFI <0.972,6 0.879
χ2 /df - Chi-square/degrees of freedom








SE 27.35 ± 4.61 26.45 ± 4.80 0.913 <0.001
SM   8.75 ± 5.83   8.55 ± 5.64 0.993 <0.001
PT   9.95 ± 3.10   9.90 ± 3.09 0.997 <0.001
PR   8.65 ± 2.06   8.70 ± 2.11 0.994 <0.001
Total 54.70 ± 8.71 53.60 ± 8.59 0.967 <0.001
OACAS  -  oral anticoagulant-use attitude scale, r - correlation,  
SE - attitude towards safe environment and food interaction, 
SM - attitude toward safe medication, PT - prevention of trauma and 
attitudes appropriate approach, PR - attitudes toward the prevention of 
potential risks
Table 4 -  Sub-dimensions and total score averages of oral anticoagulant-




SE 21  (12) 20.08±7.22 7-33
SM  6    (8)  7.64±4.46 3-15
PT 10  (5)  9.95±3.34 5-21
PR 9    (5)  9.70±3.38 5-21
OACAS 48  (19)  47.39±12.78  20-82
IQR - interquartile range, OACAS  -  oral anticoagulant-use attitude 
scale, SE - attitude towards safe environment and food interaction, 
SM - attitude toward safe medication, PT - prevention of trauma and 
attitudes appropriate approach, PR - attitudes toward the prevention of 
potential risks
Table 5 -  Pearson’s correlation coefficient between OACAS total score 
and sub-dimension scores.
 
SE SM PT PR
SM   0.426* 1 - -
PT   0.297* 0.249* 1 -
PR 0.087 0.237* 0.355* 1
Total OAC  0.814* 0.718* 0.610* 0.489*
OACAS  -  oral anticoagulant, SE - attitude towards safe environment 
and food interaction, SM - attitude toward safe medication, 
PT - prevention of trauma and attitudes appropriate approach, 
PR - attitudes toward the prevention of potential risks
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time. In the factor analysis, the variance loads and 
each sub-dimension formed were evaluated in terms of 
item sub-dimension total score correlations. Four sub-
dimensions with similar properties were obtained as a 
result of the varimax rotation of the 20-item scale.
The fact that the fit indices calculated in the frame of 
confirmatory factor analysis, especially the chi-square/
degrees of freedom were lower than three, the fact that 
the SRMR value was lower than 0.1, and the fact that 
the RMSEA was lower than 0.08 indicated that the 
scale was suitable at an acceptable level.14-20 Because the 
Cronbach’s alpha coefficients for the total scale and sub-
dimensions of the scale were sufficiently good level, half 
of the variance was explained (54.36%) and the scale 
could be considered valid and reliable. This indicated 
that the correlation between the items constituting the 
sub-dimensions and the theoretical structure of the sub-
dimension was significant. The fact that the item-total 
score was positive and sufficiently high indicated that the 
items were suitable and consistent with each other.21-23
The time OAC use and age of participants (0-6 
mounts) was a limiting factor, because certain OACAS 
questions were used for determination attitude 
development those between the ages of  above 18 years. 
Although there are limitations, the sample was derived 
from a representative sample of the Sakarya-Turkey 
population. In the literature, we have not encountered 
with no assessment instrument evaluating attitudes 
of individuals toward OAC use and considering from 
this point of view, it will be the first relevant scale in 
literature. Attitudes are important when individuals 
use OAC medicines, which can have life-threatening 
problems, while maintaining compliance with care and 
providing health behaviors. With the developed scale, 
it will be possible to determine the current attitude 
and in this direction the needs of the individual will be 
Figure 2 - Path diagram of oral anticoagulant-use attitude scale. OACAS - oral anticoagulant-use 
attitude scale.
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revealed. Health professionals will support the creation 
of educational content that they will prepare for safe use 
of the drug and behavior modification. 
It is proposed that the OAC use scale developed in 
the present study is valid and reliable for the Turkish 
population, that it can be used to determine attitudes 
towards drug use in individuals using OACs in clinics 
and in the public health area, and that it can also be 
used in studies addressing this topic comparing different 
groups. Further, the scale can be applied in international 
studies via language and community-based adaptation.
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